Compare ENR & ORKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | ORKA |
|---|---|---|
| Founded | 2015 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | N/A |
| Metric | ENR | ORKA |
|---|---|---|
| Price | $19.75 | $33.18 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | $27.00 | ★ $49.73 |
| AVG Volume (30 Days) | ★ 943.2K | 729.1K |
| Earning Date | 02-05-2026 | 03-05-2026 |
| Dividend Yield | ★ 5.80% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $2.65 | N/A |
| Revenue Next Year | $1.09 | N/A |
| P/E Ratio | $6.23 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $16.77 | $5.49 |
| 52 Week High | $35.83 | $33.85 |
| Indicator | ENR | ORKA |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 62.57 |
| Support Level | $20.85 | $25.79 |
| Resistance Level | $21.90 | $28.51 |
| Average True Range (ATR) | 0.76 | 2.13 |
| MACD | 0.02 | 0.48 |
| Stochastic Oscillator | 27.85 | 86.89 |
Energizer Holdings Inc makes and distributes household batteries, specialty batteries, and lighting products. Energizer offers batteries using lithium, alkaline, carbon-zinc, nickel-metal hydride, zinc-air, and silver oxide technologies. These products are sold under the Energizer, Rayovac, Varta and Eveready brands at performance and premium price segments. It also offers auto care products in the appearance, fragrance, performance, and air conditioning recharge product categories. The company operates in two geographical segments: Americas and International, of which the majority of its revenue is derived from the America. It has two product segments: Batteries & Lights and Auto Care. It earns maximum revenue from Batteries & Lights segment.
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.